Using aerosolized therapy to treat metastatic lung cancer
Aerosolized Epigenetic Therapy for Metastatic Lung Cancer
This study is exploring a new way to treat metastatic lung cancer by using a special inhaled therapy that may help wake up genes in cancer cells, and it's designed for patients looking for more effective treatment options.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nob Hill Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Albuquerque, UNITED STATES) |
| Project ID | NIH-10931496 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating metastatic lung cancer by using aerosolized epigenetic therapy. The therapy aims to reverse the methylation of genes that are silenced in cancer cells, potentially leading to tumor regression. By utilizing FDA-approved drugs like 5-azacytidine and 5-aza-2’-deoxycytidine, the study seeks to enhance the effectiveness of existing treatments. Patients will receive this therapy through inhalation, allowing for targeted delivery to the lungs.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic lung cancer, particularly those who have not responded well to traditional therapies.
Not a fit: Patients with early-stage lung cancer or those whose cancer has not metastasized may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that improves survival rates and quality of life for patients with metastatic lung cancer.
How similar studies have performed: While the use of epigenetic therapy in solid tumors is still emerging, there have been successful applications in blood-borne cancers, suggesting potential for similar success in lung cancer.
Where this research is happening
Albuquerque, UNITED STATES
- Nob Hill Therapeutics, INC. — Albuquerque, United States (Active)
Researchers
- Principal investigator: Reed, Matthew — Nob Hill Therapeutics, INC.
- Study coordinator: Reed, Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.